ARCHIVES

An old drug’s 21st century makeover begins with 84-fold price increase. Price hike of procarbazine astonishes brain tumor specialists.

This article is from The Cancer Letter archive.

Vol. 31 No. 19 | May 13, 2005

Download PDF Visit The Full Archive

Related Articles

DeVita Changes Mind On OSP Phase Out Reasons, But Presses for “Internalizing” Coordinating Portfolio

January 1, 1988

NIH Tells Grant Applicants One Resubmission Is Enough.

October 24, 2008

Wilding named director, Univ. of Wisconsin Cancer Center.

January 30, 2004

In Brief: NCA to Hear Reports On Outstanding Investigator Awards, Defining QRA, P01 Guidelines, Gallow Work

May 6, 1983

NCI STRAP Grants Aim To Move Research Quickly To Clinical Trials

October 1, 2010

CALGB Grant OKed, But Group May Lose Support For Its Non-Hematologic Segments

January 8, 1982